FORA: Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice

Describe the safety, tolerability, efficacy and approaches to prescribing prolgolimab in the
standard dosing regimen of 1 mg / kg every 2 weeks in patients with advanced melanoma in
routine practice.

Prolgolimab (Forteca, formerly BCD 100) is an IgG1 anti-PD-1 (programmed cell death protein
1) monoclonal antibody containing the Fc-silencing 'LALA' mutation.